Haploidentical hematopoietic stem cell transplantation using T-cell-depleted grafts is a valid option for pediatric patients with hematological malignancies in need of an allogeneic transplantation and lacking an HLA-identical donor. Seventy-five transplantations were performed in 70 patients. Thirty-eight patients had ALL, 32 had AML, 3 had advanced myelodysplastic syndromes and 2 juvenile myelomonocytic leukemia; 19 were in first CR, 30 in second CR, 12 in greater than second CR and 14 were considered to be in refractory disease at time of transplantation. Four patients developed graft failure. Among engrafted patients, the median time to neutrophil and platelet recovery was 13 (range 8-20) and 10 days (range 8-70), respectively. In 64 (85%) cases, ⩾ 1 infections were diagnosed after transplant. The probability of nonrelapse mortality by day +100 after transplantation was 10 ± 4%. With a median follow-up of 22 months, the probability of relapse was 32 ± 6% and disease-free survival was 52 ± 6%. Haploidentical transplantation using CD3/CD19 depletion is associated with encouraging results especially in patients in early phase of disease. Killer-cell Ig-like receptor B haplotype donors confer a rapid natural killer cells expansion early after transplantation, resulting in lower probability of relapse and suggesting a GvL effect apart from graft-versus-host reactions. Donor infusion of high numbers of CD34+ cells is recommended in order to improve T-cell reconstitution.
INTRODUCTION
Haploidentical hematopoietic stem cell transplantation (HSCT) using T-cell-depleted grafts is currently a valid option for pediatric patients with hematological malignancies in need of an allogeneic transplantation who lack an HLA-identical donor. The use of CD3/CD19 depletion as a graft manipulation method helps retain large numbers of important immune cells in the graft as well as 'unaltered' CD34 + cells. As previously described, [1] [2] [3] [4] [5] we have observed persistent and more accelerated engraftment compared with CD34 + selection (without megadoses of CD34 + stem cells) by using CD3/CD19-depleted haploidentical grafts and fludarabinebased reduced toxicity regimens.
However, few studies have reported the prognostic factors and outcomes in this type of transplantation. The aim of this prospective study was to analyze the outcomes and risk factors for survival of pediatric patients who received an allogeneic transplant from a mismatched and/or full haploidentical relative donor using a CD3/CD19-depleted graft.
MATERIALS AND METHODS

Patient and donor characteristics
Patients were enrolled in the study from January 2005 to December 2013. We included pediatric patients diagnosed with high-risk hematological malignancies in need of an allogeneic transplantation and in good clinical condition who lacked either a matched related donor or a matched unrelated donor. The indications for stem cell transplantation in CR1 included, for children with ALL, induction failure (defined as no remission at 1 month following induction treatment), poor cytogenetics, persistent minimal residual disease tested by PCR before transplant (1 month) with a cutoff point of 10 − 3 ; presenting intermediate or poor risk was the criterion for children with AML. The only exclusion criterion was a poor clinical condition, defined as a Lansky score lower than 60%. The study protocol was approved by the local ethics committees, and informed consent was obtained from the patients or their legal guardians. The patient and transplantation characteristics are shown in Table 1 . Child was defined as o12 years and teenager as ⩾ 12.
Seventy-five transplantations were performed on 70 patients. Thirtyeight patients had ALL, 32 had AML, 3 had advanced myelodysplastic syndrome (refractory anemia with excess blasts in transformation) and 2 had juvenile myelomonocytic leukemia. Nineteen of the 70 patients were in first CR, 30 were in second CR and 12 were in more than second CR. Fourteen patients were considered to have refractory disease at the time of transplantation. Primary refractory AML was defined as the failure to achieve a response after one or two cycles of induction. Refractory ALL was defined as the failure to achieve a cytological remission response after induction chemotherapy and second-line rescue chemotherapy.
Haploidentical transplantation was the first transplant in 51 cases. In 24 cases, one or two previous stem cell transplantations and subsequent chemotherapy courses before haploidentical transplantation were performed. All donors were ⩾ 2 HLA-loci mismatched parents (48 mothers and 19 fathers) or siblings (n = 8). Patients receiving a second or third transplant received the rescue regimen before a new transplantation. Donor evaluation included eligibility for mobilization, crossmatch testing, CMV serological status, presence of killer-cell Ig-like receptor (KIR) mismatches and a KIR genotype.
KIR genotyping and KIR ligand (HLA-I typing)
Fifteen human KIR genes and two pseudogenes were analyzed by PCR with a KIR typing kit (Miltenyi Biotec, Bergisch Gladbach, Germany). The KIR A haplotype was defined by the absence of 2DS1, 2DS2, 2DS3 and 3DS1 and the presence of 2DS4 as the only KIR-activating receptor. The KIR B haplotype was determined by the presence of any activating genes except 2DS4. 6 The KIR ligand HLA-C allotypes (C1 and C2) and the HLA-B allotypes (Bw4) were determined using high-resolution PCR-sequence-based typing. We also determined KIR B-content scores for all donors according to the system proposed by Cooley et al. (www.ebi.ac.uk/ipd/kir/donor_b_content. html). Donor characteristics are shown in Table 2 .
Hematopoietic stem cell mobilization, collection, graft manipulation and infusion
The donor PBSCs were mobilized by administering granulocyte CSF (10 μg/kg per day for 4 days) and were harvested by 1-2 leukapheresis procedures.
All graft manipulation procedures for T-cell depletion were performed in our JACIE (Joint Accreditation Committee of the International Society for Cellular Therapy (Europe) and European Society for Blood and Marrow Transplantation)-accredited unit following standard operating procedures. All of the procedures were based on immunomagnetic CD3 + /CD19 + cell depletion. CD34 + cell selection was used in five cases as a stem cell 'boost' because of poor marrow function or impending graft failure.
All immunomagnetic procedures were performed according to the manufacturer's standard protocol, using the CliniMACS device. The final products were analyzed by flow cytometry on a FACSCanto II cytometer (BD Biosciences, San Agustín de Guadalix, Madrid, Spain). Finally, the cell product was freshly infused via a central venous catheter.
Transplant protocol
The conditioning regimen consisted of fludarabine (25 mg/m 2 day from days − 6 to − 2), busulfan (3.2-4.8 mg/kg/day, according to patient body weight, from days − 6 to − 4) and thiotepa (5 mg/kg/day from days − 3 to − 2). Methylprednisolone was administered on days − 6 to − 2 (5 mg/kg). For those patients who needed a second haploidentical transplantation, the conditioning regimen consisted of fludarabine 40 mg/m 2 /day from days − 5 to − 3, thymoglobulin 2 mg/kg/day from days − 5 to − 3 and melphalan 120 mg/m 2 on day − 1.
GvHD prophylaxis and supportive care
The GvHD prophylaxis regimen consisted of cyclosporine A at a dose of 3 mg/kg/day given IV from day − 1. The administration of cyclosporine A was tapered as soon as possible, typically before day 30 if GvHD was absent. In addition, these patients received a T-cell-depleted graft. PCR screening for CMV, adenovirus and EBV was performed weekly. All patients were administered prophylactic acyclovir, micafungin and trimethoprim-sulfamethoxazole. The initial management of CMV reactivation consisted of ganciclovir (5 mg/kg IV every 12 h). Empiric management of invasive fungal infection consisted of liposomal amphotericin B (3-5 mg/kg IV every 24 h).
Assessment of engraftment, chimerism status, antibodies and flow cytometry analysis for immune reconstitution following transplantation Myeloid recovery was defined as the first of 3 consecutive days on which the absolute neutrophil count was 40.5 × 10 9 /L. Platelet recovery time was considered the first of 3 consecutive days on which a platelet count above 20 × 10 9 /L was achieved, with no transfusion requirements. Chimerism was evaluated by the short tandem repeat PCR method at the time of engraftment and monthly following transplantation. Donor chimerism was determined for whole blood and cell subsets. For the chimerism analysis in sub-populations, CD34 + progenitor cells from bone marrow and T lymphocytes from peripheral blood were purified by immunomagnetic methods (CD34 or CD3 beads; Miltenyi Biotec). Phenotyping of natural killer (NK) cells, T lymphocytes, T lymphocyte subsets, B lymphocytes, NKT lymphocytes and dendritic cells (DCs) was performed on fresh samples of whole blood by multiparametric flow cytometry as previously described. 7 The following fluorochrome-labeled monoclonal Abs against human Ags were obtained from Becton Dickinson (San Jose, CA, USA): CD3 PE-Cy7, CD20-PE, CD45-FITC, lineage-FITC, HLADR-APC-Cy7, CD11c-PECy5, CD45RA-PE-Cy5 and CCR7-PE. Fluorochrome-labeled monoclonal Abs against CD19-PE, CD56-APC and CD25-PE were obtained from Beckman Coulter (Fullerton, CA, USA). Fluorochrome-labeled monoclonal Abs against BDCA4-APC were obtained from Miltenyi Biotec.
Study design, definitions and statistical analysis
The major study endpoints were disease-free survival (DFS), cumulative relapse incidence and nonrelapse mortality (NRM). Acute GvHD (aGvHD) was graded according to standard criteria, whereas chronic GvHD (cGvHD) was defined as mild, moderate and severe in patients surviving 4100 days following transplantation. Relapse was defined as morphologic or clinical evidence of recurrence in the peripheral blood, bone marrow or extramedullary sites. NRM was defined as any cause of death other than disease. The DFS rate was calculated from the time of transplantation by means of the Kaplan-Meier product limit method. Cumulative incidence was used to estimate the relapse and NRM rates. The multivariate analysis of survival was evaluated using the Cox proportional hazard regression model. Hazard ratios (HRs) were calculated with a 95% confidence interval Abbreviations: ALL = acute lymphoblastic leukemia; AML = acute myeloblastic leukemia; CR = complete remission; JMML = juvenile myelomonocytic leukemia; MDS = myelodysplastic syndrome; MRD = minimal residual disease. 
RESULTS
Engraftment kinetics and supportive care
Four patients developed graft failure (two primary and two secondary) but were all rescued using the same donor as a second haploidentical transplant. Two of them recovered and the other two died, one as a result of toxicity and the other because of relapse. The graft failure rate was 13 ± 4%. We were not able to identify risk factors for engraftment failure because of the low number of patients. The median time to neutrophil recovery for the patients with engraftment was 13 days (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) . The median time to platelet engraftment was 10 days (8-70), and the median times to platelet counts of 50 × 10 9 /L and 100 × 10 9 /L were 13 days (9-150) and 15 days (9-150), respectively. Patients required platelet transfusions for a median of 3 days (0-40), and the median duration of the red blood cell transfusions was 2 days (0-20). The median durations for fever and antibiotic treatment were 1 day (0-15) and 12 days (0-40), respectively. The toxicity profile is shown in Table 3 . It is worth remarking that 17 patients (22%) developed engraftment syndrome (ES), and in 18 cases (24%) liver toxicity was observed. However, there were no cases of veno-occlusive disease.
In 64 (85%) cases, one or more infections were diagnosed after transplantation, and 118 different pathogens were diagnosed. There were 70 (59%) cases caused by virus, 40 (34%) by bacteria and 8 (7%) by fungi. Of the viral infections, CMV (reactivation and/or disease) was the most frequent pathogen. The median hospitalization time after hematopoietic cell infusion was 15 days (10-120).
Chimerism kinetics Chimerism was studied in all patients. The evaluation of chimerism in the bone marrow samples performed after hematological recovery showed 99% donor origin in the CD34 + cell population for all patients with engraftment.
Immune reconstitution
The immune reconstitution was characterized in all patients with engraftment by a rapid increase in NK cells (Figure 1) . The cell counts peaked on day 30 (median of 352/μL (3-1895)). However, the patients who received a transplant from a donor with haplotype B had a higher number of NK cells compared with those receiving a transplant from an haplotype A donor (median of GvHD and NRM Thirty patients developed aGvHD (grade 1, n = 13; grade 2, n = 8; grade 3, n = 6; and grade 4, n = 3). The GvHD (grade 2 or higher) rate was 35 ± 6%. The median time to aGvHD was 30 days (10-90 days). Twenty-three patients developed cGvHD (mild in 10 cases, moderate in 10 cases and severe in 3 cases), with a Kaplan-Meier value of 46 ± 7%. The median time to cGvHD was 129 days (76-306 days). The probability of NRM by day 100 after transplantation was 10 ± 4%. Seven patients died by day 100, with a median time to death of 64 days (30-89), whereas seven patients died after day 100. The NRM rate was 23 ± 5%, with a median time to death of 93 days (30-564 days) at 2 years following transplantation. The patients who died at this time had a lower number of CD3 + cells compared with the surviving patients (median CD3 + cell count of 70/μL (0-1220) vs 283/μL (18-4242), respectively; P o0.05); CD3 + cell count was performed at day +60 and only one patient died before that day. The univariate analysis found that disease phase at transplantation (early 6 ± 5% vs other 28 ± 7%; P = 0.05) and patient age (teenager 42 ± 11% vs nonteenager 14 ± 6%; P = 0.003) were the risk factors associated with NRM. However, in the multivariate analysis only age (teenager) was associated with NRM (HR 4.54; 95% CI 1.49-13.3; P = 0.007). The primary causes of death are shown in Table 4 .
Relapse and DFS Seventeen patients relapsed, with a median time to relapse of 160 days (23-617 days), and the relapse rate was 32 ± 6%. The following variables influenced the relapse rate in the univariate analysis: disease phase at the time of transplantation (early phase, 0%; intermediate, 47 ± 11%; and advanced phase, 40 ± 11%; P = 0.02), B haplotype donor compared with A haplotype donor (16 ± 6% vs 86 ± 12%, respectively; P o0.0001), high number of NK cells on day 30 compared with low number (13 ± 6% vs 54 ± 10%, respectively; P = 0.004) and presence or absence of cGvHD (16 ± 8% vs 44 ± 9%, respectively; P = 0.001). No other variable was associated with relapse. However, in the multivariate analysis the only variable that influenced the relapse rate was the donor haplotype (B haplotype; HR 0.14; 95% CI 0.05-0.39; P o 0.0001).
The DFS rate was 52 ± 6%. The following variables influenced the DFS rate in the univariate analysis: disease phase at the time of transplantation; early phase compared with non-early phase (93 ± 6% vs 40 ± 7%, respectively; Po0.001), Figure 2a ; patient age: child compared with teenager (57 ± 7% vs 41 ± 10%, respectively; P = 0.04), Figure 2b ; haplotype B donor compared with haplotype A donor (67 ± 7% vs 8 ± 7%, respectively; Po0.0001), Figure 2c ; number of NK cells on day 30: ⩾ 350/μL compared with o350/μL (69±8% vs 35 ± 9%, respectively; P = 0.01); and the presence or absence of cGvHD (72 ± 10% vs 40 ± 8%, respectively; P = 0.004), Figure 2d . However, in the multivariate analysis all variables mentioned above except the number of NK cells on day 30 were found to be associated with DFS (Table 5) .
DISCUSSION
The availability of a suitably matched donor has limited the use of allogeneic HSCT, which has been considered as the only curative treatment for pediatric patients with high-risk leukemia. For patients in need of an allogeneic transplantation in a timely manner, the use of mismatched/haploidentical-related donors has therefore been considered an optimal approach. Considering grafts not only contain CD34 + cell progenitors but CD34 -progenitors, NK, dendritic and facilitating cells as well, graft manipulation by means of CD3/CD19 depletion for allogeneic transplantation has led to improved engraftment and immune reconstitution. 8 This prospective study was designed to evaluate the use of graft manipulation by means of CD3/CD19 depletion from mismatched/haploidentical-related donors in patients with high-risk pediatric leukemia who lacked a matched donor. The primary findings of this study are presented below.
First, as expected, the engraftment kinetics were rapid (particularly for platelet engraftment), which was probably due to the large number of infused progenitors, as has been recently published. 9 Graft composition was significantly modified by graft manipulation, which may have influenced platelet engraftment. As other authors have noted, grafts selectively depleted of T and B cells may contain more graft-facilitating cells and CD34 + cells, enhancing engraftment and immune recovery. 8 The rapid engraftment observed strongly suggests, as previously published, the feasibility of a successful allogeneic HSCT in the mismatched/ haploidentical setting, even with no CD34 + cell megadose. 8 Although a small number of patients developed primary or secondary graft failure, all but one were rescued using a second allograft. We were unable to identify any risk factors for engraftment failure because of the rarity of this event. This finding is in line with that published by other authors who used various conditioning regimens, including serotherapy and/or TBI. [10] [11] The use of serotherapy-based conditioning regimens has been associated with delayed immune recovery, particularly CD4 + lymphocyte subsets, which may increase the risk of opportunistic infections during the early phase after transplantation. Moreover, TBI-based regimens are associated with more transplant-related toxicity and more late effects, especially in low-weight pediatric patients. Non-radiation-based preparative regimens can be used in pediatric patients with high-risk acute leukemia 12 and fludarabine-based reduced-intensity conditioning regimens are safe and effective alternatives to TBI in HSCT. An important observation in this study was the fact that the conditioning regimen was well tolerated, with a low incidence of severe complications, similar to that of recently published reports. 9 The incidence of ES is also remarkable. ES and pre-ES are both inflammatory conditions that occur after HSCT and are characterized by non-infectious fever and skin rash. Although the pathogenesis is not fully understood, both syndromes are similar, and could be defined as a new clinical syndrome, named as peri-ES. 13 Although this complication has been previously reported in a pediatric transplantation setting, there are no reported data regarding ES in haploidentical pediatric transplantation. The reported incidence of ES in children ranges from 19% to 48% and has been considered a risk factor for developing aGvHD and cGvHD. [14] [15] [16] In our series, this complication had no impact on outcomes.
The second finding was that the immune recovery analysis showed a rapid reconstitution of some lymphocyte subsets. Faster and sustained NK cell reconstitution was observed over time, particularly in patients receiving a transplant from a haplotype B donor compared with a haplotype A donor. This was the only variable associated with NK cell reconstitution, and this is the first time it has been reported in haploidentical pediatric transplantation. We found no association between NK cell reconstitution and other variables, such as the number of infused CD34 + and NK cells or the impact of a KIR donor-recipient mismatch. A relevant and previously reported feature of NK cell reconstitution 17 was the impact on the relapse rate after transplantation. The patients with high NK cell counts by day 30 after transplantation had a lower incidence of disease relapse than the patients with low NK cell counts. Although other variables were found to influence the relapse rate in the univariate analysis, in the multivariate analysis the only one that had a relevant impact was the use of KIR B haplotype donors. This has been reported to confer a reduced risk of relapse in children with ALL receiving a haploidentical transplant, 18 and in our study this was also true for patients with myeloid malignancies. This finding has an important impact on our policy of donor selection. Similarly to other authors, 18, 19 we recommend that related donors with KIR B genotypes may be used for pediatric patients with ALL and AML in the haploidentical transplantation setting.
In contrast to the rapid NK cell reconstitution, T-cell recovery was delayed. This finding is in line with those previously reported by other authors in prospective and retrospective studies. 20, 21 As published elsewhere, 22 we found that T-cell reconstitution was also influenced by the number of infused CD34 + cells. The slow T-cell reconstitution was clearly related to the risk of opportunistic and mostly viral infections. Furthermore, patients who died because of infections had a significantly lower number of peripheral blood T cells at the time of death compared with those who survived. In fact, opportunistic infections were the leading cause of NRM and the second leading cause of transplant failure after relapsing disease. The only variable that was associated with NRM was age, perhaps representing other factors such as more advanced disease at the time of transplantation and/or a lower number of infused CD34 + cells per kg of body weight.
The third finding was the remarkable incidence of cGvHD, which has not been reported in this kind of allogeneic transplantation. The efficiency of T cell depletion with CD3/CD19 was lower than CD34 + selection with a 3.5-4log depletion, although this correlated to increased rates of GvHD because CD3/CD19-depleted grafts contained approximately a threefold number of CD3 + cells. Leung et al. 23 reported a 25.7% incidence of grades II-IV GvHD. However, other studies saw a 55% of grades II-IV aGvHD in patients receiving CD3/19-depleted grafts. 1 Although most patients developed mild or moderate cGvHD, it developed to severe in nearly 10% of them, requiring protracted treatment. However, cGvHD was associated with better DFS, primarily due to lower relapse incidence.
Despite the high proportion of patients in an advanced state of the disease at the time of transplantation, we consider DFS was acceptable taking into account the diagnoses and stages of disease of the study population ( Figure 2 ). As expected, it was particularly long for the patients receiving their first transplant and in their first CR. A more important result is that a relevant proportion of the patients who underwent transplantation at a more advanced phase of the disease or even with active disease were rescued by haploidentical transplantation. A number of these patients had been in CR for a long time. Although the median follow-up is not long enough to consider the results as mature, we believe they are encouraging and support the idea of using haploidentical donors as early as possible whenever a patient needs an HSCT. These results compare favorably, at least in our experience, with those obtained using unrelated donors. 24 Several conclusions can be drawn from these results. First, haploidentical transplantation using CD3/CD19 depletion yields encouraging results, especially for patients in the early phase of the disease. Second, KIR B haplotype donors confer rapid NK cell proliferation soon after transplantation, resulting in a lower relapse rate and suggesting a GvL effect separate from graftversus-host reactions. Donor selection should be based on this finding. Third, the infusion of high numbers of CD34 + cells is recommended to improve T-cell reconstitution, particularly in adolescents.
